A to Z of investigational drugs

Drugs in the pipeline.

  • 2248761 (IDX899, GSK2248761)

    2248761 (formerly IDX899, GSK 2248761) is a non-nucleoside reverse transcriptase inhibitor in development by ViiV Healthcare, a specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer.  In vitro

  • AMD070

    AMD070 is an investigational drug belonging to a new class of drugs known as CXCR4 inhibitors. It stops the process of HIV attachment and entry into CD4

  • Apricitabine (AVX754, SPD754)

    Apricitabine is a nucleoside reverse transcriptase inhibitor that is active against the M184V mutation and to other thymidine-associated mutations. It interferes with the process of HIV replication by imitating the nucleosides, or building

  • Bevirimat (PA-457 or MPC-4326)

    Bevirimat is the first experimental HIV maturation inhibitor. Development of bevirimat has been halted by its developer, Myriad Genetics.Maturation inhibitors reduce HIV viral load by

  • Cobicistat

    Gilead Sciences is conducting human studies of a product that could replace ritonavir as an antiretroviral boosting agent in some fixed-dose combinations. Cobicistat, formerly known

  • CTP-518

    CTP-518 is a novel HIV protease inhibitor from Concert Pharmaceuticals that replaces certain key hydrogen atoms of atazanavir with deuterium, a heavier, non-radioactive relative of

  • Elvitegravir (GS 9137)

    Elvitegravir (formerly GS 9137 and JTK-303) is a promising integrase inhibitor in late clinical development by Gilead Sciences. When studied in treatment-experienced patients with extensive drug resistance, viral load was

  • Elvucitabine (ACH-126)

    Elvucitabine (formerly, ACH-126) is a cytosine analogue similar to 3TC (Epivir) and FTC (Emtriva). It is being developed by Achillion Pharmaceuticals. Interim 48-week data from a phase II trial in treatment-naive

  • GS-8374 (TMC-126)

    GS-8374 (formerly TMC-126) is a protease inhibitor being developed by Gilead Sciences. It adds a phosphonate group onto a protease inhibitor; the corresponding prodrug is able

  • GSK-572

    S/GSK1349572, or GSK-572 for short, is a second-generation integrase inhibitor being developed jointly by Shionogi of Japan and ViiV Healthcare.Laboratory and early clinical studies showed that GSK-572

  • HGS004

    HGS004 is a human immunoglobulin (Ig) G4 monoclonal antibody against CCR5 that is being developed by Quest Clinical Research. HGS004 binds to and inhibits the activity of

  • INCB009471

    INCB009471, an investigational CCR5 antagonist, appears to be potent and well tolerated, according to results of a small phase IIa study presented in 2007. The

  • Minocycline

    Minocycline is an antibiotic that has been used since the 1970s for treating acne. Reports now indicate that minocycline effectively targets infected immune cells in

  • PPL-100

    PPL-100 is a protease inhibitor drug developed by Ambrilia. The drug was licensed to Merck until 2008 when it was returned to Ambrilia. It is currently

  • PRO 140

    PRO 140, developed by Progenics Pharmaceuticals, is a CCR5 monoclonal antibody that binds to the extracellular domain rather than the transmembrane pocket. In a phase II dose-ranging

  • Racivir

    Racivir is an experimental anti-HIV drug that belongs to the class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). These drugs interfere with the

  • RDEA806

    RDEA896 is a new NNRTI, developed by Ardea Biosciences, with a high barrier to resistance against the common mutations that develop with efavirenz and nevirapine. A

  • SCH532706

    A 'second-generation' small molecule CCR5 antagonist, SCH532706, boosted with ritonavir, demonstrated potent anti-HIV activity and was generally well-tolerated in a small ten-day monotherapy study according to

  • SPI-452

    SPI-452 from Sequoia Pharmaceuticals is another pharmacokinetic enhancer that, in animal studies, was able to boost levels of the protease inhibitors saquinavir, lopinavir, and atazanavir. In a phase

  • TBR-652

    TBR-652 is a CCR5 antagonist being developed by Tobira Therapeutics. The drug has a half-life in the body of 35 to 40 hours. Phase I

  • TNX-355

    TNX-355, a genetically engineered monoclonal antibody that acts on the CD4 receptor, has shown considerable promise. TNX-355 targets a part of the CD4 receptor that

  • UK-453,061

    UK-453,061 (lersivirine), a Pfizer drug now being developed by ViiV Healthcare, is a second-generation NNRTI. It does not seem to have a significant effect on CYP3A4

  • Vicriviroc (SCH-D)

    Vicriviroc is a CCR5 antagonist originally developed by Schering-Plough’s  and previously known as SCH-D and SCH-417690. Merck & Co., Inc. acquired vicriviroc in its merger with Schering

  • Vivecon (MP-9055)

    According to developer Myriad Genetics MP-9055 (Vivecon), an experimental HIV maturation inhibitor, is entering phase IIA clinical trials in antiretroviral-naive HIV-positive patients.  Completed phase I dose-ranging

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap